Literature DB >> 22966961

The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis.

J D Pauling1, V B O'Donnell, N J Mchugh.   

Abstract

Raynaud's phenomenon (RP) describes the excessive vascular response of the digital vessels in response to cold exposure and emotional stress. It is typically the earliest manifestation of systemic sclerosis (SSc), a multisystem disease of unknown aetiology characterised by vasculopathy, inflammation and fibrosis. The biological actions of platelets are known to extend beyond primary haemostasis with a growing appreciation of their contribution to vascular function, inflammation and wound repair. This has led to a considerable body of work evaluating associations between platelet function analysis and RP/SSc. This review provides a conceptual framework upon which the potential contribution of platelets to vascular dysfunction, autoimmunity and tissue remodelling in RP and SSc is considered. We describe the existing evidence to support excessive platelet activation in RP and SSc, ranging from the early studies of platelet aggregability and circulating platelet-derived mediators, to the important findings of the recent work that has begun to explore the potential direct pathogenic role of platelets in established murine models of SSc. We shall describe and critically appraise the findings of previous therapeutic studies evaluating the use of anti-platelet agents in RP and SSc, along with their implications for future therapeutic intervention in these conditions.

Entities:  

Mesh:

Year:  2012        PMID: 22966961     DOI: 10.3109/09537104.2012.719090

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  9 in total

Review 1.  Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.

Authors:  Oliver Distler; Antonio Cozzio
Journal:  Semin Immunopathol       Date:  2015-11-17       Impact factor: 9.623

2.  Fluoxetine and Raynaud's phenomenon: friend or foe?

Authors:  Charles Khouri; Thomas Gailland; Marion Lepelley; Matthieu Roustit; Jean-Luc Cracowski
Journal:  Br J Clin Pharmacol       Date:  2017-06-04       Impact factor: 4.335

Review 3.  Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders.

Authors:  Saion Chatterjee; John D Pauling
Journal:  Clin Rheumatol       Date:  2020-09-21       Impact factor: 2.980

4.  Mean platelet volume is elevated in patients with psoriasis vulgaris.

Authors:  Dae Suk Kim; Jungsoo Lee; Sung Hee Kim; Soo Min Kim; Min-Geol Lee
Journal:  Yonsei Med J       Date:  2015-05       Impact factor: 2.759

5.  Microparticle subpopulations are potential markers of disease progression and vascular dysfunction across a spectrum of connective tissue disease.

Authors:  E M McCarthy; D Moreno-Martinez; F L Wilkinson; N J McHugh; I N Bruce; J D Pauling; M Y Alexander; B Parker
Journal:  BBA Clin       Date:  2016-11-10

Review 6.  Platelets in Skin Autoimmune Diseases.

Authors:  Xiaobo Liu; Christian Gorzelanny; Stefan W Schneider
Journal:  Front Immunol       Date:  2019-07-04       Impact factor: 7.561

7.  A Correlative Study between Platelet Count, Mean Platelet Volume and Red Cell Distribution Width with the Disease Severity Index in Psoriasis Patients.

Authors:  Vijayashree Raghavan; Rajesh Kanna Nandagopal Radha; Ramesh K Rao; Abinaya Kuberan
Journal:  J Clin Diagn Res       Date:  2017-09-01

Review 8.  Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis.

Authors:  Pier Andrea Nicolosi; Enrico Tombetti; Norma Maugeri; Patrizia Rovere-Querini; Silvia Brunelli; Angelo A Manfredi
Journal:  Stem Cells Int       Date:  2016-03-16       Impact factor: 5.443

9.  Platelet Count and Mean Platelet Volume in Psoriasis Patients.

Authors:  Ezgi Özkur; Sıla Şeremet; Fatma Şule Afşar; İlknur K Altunay; Emel E Çalıkoğlu
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2018-12-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.